The profile of T-cell receptor beta-chain variable (TRBV) genes usually skews in subjects with virus infection or cancer. The gene melting spectral pattern (GMSP) can be used to determine the profile of the TRBV gene family. To explore the portrait of the TRBV family in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection (AHI), peripheral blood mononuclear cells (PBMCs) were separated and further sorted into CD4
INTRODUCTION
Hepatitis B virus (HBV) infection remains a global public health problem. According to a 2010 report from the World Health Organization, approximately two billion people were infected with HBV worldwide, of which 350 million had chronic HBV infection. Of those infected, approximately one million died each year from liver disease related to HBV infection. 1 Chronic HBV infection has been positively correlated with morbidity from a spectrum of liver diseases, including chronic hepatitis B, liver cirrhosis, liver failure and hepatocellular carcinoma. 2 The age of subjects is the most important factor affecting the outcome of HBV infections. Ninety percent of subjects infected with HBV perinatally or 25%-30% of infants will develop chronic HBV infection. However, only 5%-10% of individuals infected with HBV after 5 years of age will develop chronic HBV infection, and 90% of infected people will recover after presenting with acute HBV infection without any clinical symptoms. 3, 4 In the peripheral blood of subjects who recovered from AHI (recovered AHI subjects), polyclonal and polyspecific cytotoxic T lymphocytes and T helper cells develop against 1 antigenic peptides of HBV, and protection with hepatitis B surface antibodies (HBsAbs) subsequently emerges.
In general, clonal or oligoclonal T cells in the peripheral circulation of patients with viral infection appear to be antigen-specific T cells. The composition and function of specific T cells can be determined by the T-cell receptor (TCR) profile in their membranes. 5 There are several reports that address the immunological characteristics of recovered acute hepatitis B virus infection (AHI) subjects. 6, 7 However, the molecular characteristics of TCR gene families in the peripheral blood from recovered AHI subjects have not been well characterized. In previous studies, we have developed and used gene melting spectral pattern (GMSP) to monitor T-cell receptor beta-chain variable (TRBV) gene distribution and monoclonality. 8, 9 In the current study, this technique was used to detect the distribution of TRBV complementary determining region 3 (CDR3) gene families expressed in peripheral blood mononuclear cells (PBMCs) and T-cell subsets separated and isolated from recovered AHI subjects. The TRBV families were sequenced and analyzed when the shapes of their GMGP profiles presented single peaks. This study will help clarify the molecular portrait of TRBVs in peripheral blood from recovered AHI subjects and the role of cellular immunity in the pathogenesis of AHI as well as assist in the diagnosis and provision of individualized treatment for chronic HBV infection.
MATERIALS AND METHODS

Subjects
Between February and June 2012, 38 subjects who had recovered from AHI were enrolled in our study. The subjects were selected in the health examination center of the First Affiliated Hospital, College of Medicine, Zhejiang University. The diagnoses for the recovered AHI subjects were categorized based on normal biochemical markers of liver function: no previous history of hepatitis, positive for the HBsAb and/or hepatitis B core antibody without any clinical symptoms, the absence of the hepatitis B surface antigen (HBsAg) and HBV DNA levels below the detection limit. Moreover, the chosen subjects had not previously been vaccinated with the hepatitis B vaccine. Our diagnostic criteria for recovered AHI subjects complied with the proposal of the prevention and treatment for viral hepatitis (2000, Xi'an), 10 and the criteria for AHI diagnosis have also been described in other reports.
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Co-infection with hepatitis A, C, D or E, the Epstein-Barr virus or overt cytomegalovirus was ruled out according to negative serologic test results. Confounding etiologies of liver disease, human immunodeficiency virus infection, and other infectious diseases were not found in any subject. Patients diagnosed with autoimmune diseases, blood diseases or other malignancies were also excluded. The 27 healthy controls were negative for all HBV serological markers and displayed no clinical or laboratory evidence of other infectious diseases or immunological disorders. Additional characteristics of enrolled subjects at the time of the study are shown in Table 1 .
The study was approved by the local research ethics committee (Medical Ethics Committee of the First Affiliated Hospital, Zhejiang University, Hangzhou, China) in accordance with the 2008 Declaration of Helsinki, and all subjects provided written informed consent.
Biochemical, serological and virological assays
Biochemical indicators of liver function were determined using an automatic biochemical analyzer (HITACHI 7600, Japan) in the clinical laboratory center of our unit. Serum samples were tested for HBsAg, HBsAb, hepatitis B e antigen and antibodies to hepatitis B e antigen and HBcAg using enzyme immunoassays (Abbott Laboratories, Chicago, IL, USA) according to the manufacturer's instructions. Serum HBV DNA was quantitatively detected using real-time polymerase chain reaction (PCR) with commercial kits as described previously. 12 The minimal detection standard for PCR contained 500 copies/ ml. HBV genotypes were determined with sequence detection via PCR. All products were directly sequenced with an HBV Genotype Real Time PCR Kit (ZJ Bio-Tech, Shanghai, China) and run on MegaBACE 500 according to the manufacturer's instructions, as has been previously described in detail. 12 PBMC separation and T-cell subset sorting PBMCs were prepared from whole blood treated with 10 ml of fresh EDTA-K 2 anticoagulate by a Ficoll-Paque density gradient separation (CEDARLANE, Burlington, CANADA). Because we could not recover enough PBMCs useful for sorting T cells into subsets, PBMC samples were taken from 30 of 38 recovered AHI subjects and 25 of 27 healthy controls for further sorting. The positive selection for CD4 1 and CD8 1 T cells was performed using anti-CD4 and anti-CD8 monoclonal antibodies with magnetic activated cell sorting according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Each T-cell subset purity was shown to be greater than 90% (data not shown), as determined with flow cytometry using mouse anti-human antibodies CD4-FITC and CD8-PE (BD Biosciences, San Jose, CA, USA). GMSP analysis of the TRBV gene family Real-time PCR reactions were performed with 0.5 ml of cDNA sample in an amplification mixture of 25 ml for each TRBV gene family. Following a PCR-product melting curve analysis, the peak shape pattern of the melting curve for the 24 TRBV gene families was determined by plotting the negative of the first derivative of the reduction in the fluorescence signal (2dF/ dT) as a function of temperature (T m ) and the GMSPs of the TRBV families were determined, as has been described in more detail previously. 8 Gene segments from TCR beta chain constant 1 (TRBC1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were added to each reaction as internal reference controls for monoclonal expansion, and a PCR reaction without template was used as a blank control. The primers were designed for the TRBV family as previously reported, 13 and the primers used in this study are provided in Supplementary Table 1) .
Skewed TRBV gene family identification Skewed TRBV gene families were identified by GMSP profile using Opticon Monitor 3.0 software attached to a MJ Opticon 2 DNA engine (Bio-Rad, Hercules, CA, USA) and then divided into two categories: (i) 'oligoclonal expansion', which appeared as a main peak associated with other small peaks and a small peak with a height less than fifth-eighths the height of the main peak, and (ii) the 'monoclonal' category, which appeared as one main peak and, in some instances, a short small peak with a height less than three-eighths the height of the main peak. If the height of any secondary peak was more than fiftheighths the height of the main peak, the TRBV gene family was categorized as a multiclonal expansion (not skewed), which is a development of our previously published reports.
14 Relative quantification of each TRBV gene family To quantify the relative expression of each TRBV gene in recovered AHI subjects, the relative expression of a single TRBV family in PBMCs was evaluated. The expression of each TRBV gene was calculated based on the signal strength in a real-time PCR reaction and expressed as the ratio of the copy number of TRBV relative to GAPDH (RBV x~2 C t GAPDH ð Þ {C t BV x ð Þ), where Ct refers to the threshold cycle. The relative percentage (%) of TRBV x gene expression was calculated according to the following formula, which was modified from previous reports: 15, 16 TRBV x~R BV x |100
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Cloning and sequencing of monoclonal TRBV gene families The GMSP profile of a TRBV gene family showing a single peak was selected for cloning and sequencing to determine the degree of homogeneity within the CDR3 region. This process is described in our previous report. 17 The resulting TRBV gene sequences were translated into the corresponding amino-acid sequence using Chromas software (version 2.22; Technelysium, QLD, Australia), and BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to define the CDR3 and BJ segments in the TRBV families.
HLA genotype determination
Genomic DNA was extracted from EDTA-treated peripheral whole blood, and the major histocompatibility complex (MHC) class I and class II haplotypes of enrolled subjects were determined by PCR and sequence-specific oligonucleotideprobe hybridization, as has been described in more detail in previous reports. 16, 18 Statistical analysis All data were analyzed using SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA). Differences in skewed TRBV frequencies between PBMC and CD4 1 T-cell and CD8 1 T-cell populations from recovered AHI subjects were analyzed using the Kruskal-Wallis H test or the Mann-Whitney non-parametric U test. Differences between two TRBV families were examined using a x 2 test or Student's t-test with P,0.05 considered to be statistically significant.
RESULTS
Biased TRBV families within T-cell repertoires in recovered AHI subjects
Biased TRBV families were compared between the two sorted cell populations (30 samples) and the 38 PBMC samples isolated from recovered AHI subjects. Among the three cell populations analyzed, the average number of biased oligoclonal and monoclonal TRBV families in the CD8 1 T-cell subset was higher than in the CD4 1 T-cell subset or in PBMCs (P,0.01). There was no significant difference between the latter two groups (P.0.05) ( Table 2 ). In addition, there was a higher number of monoclonally expanded TRBV patterns in the CD8
1 fraction compared to the CD4 1 fraction (Figures 1  and 2 and Table 3 ). However, the number of oligoclonal TRBV families expressed in the CD4 1 T-cell and CD8 1 T-cell populations of recovered AHI subjects was not significantly different (P.0.05) ( Figure 2 and Table 3 ).
Comparison of TRBV frequency between recovered AHI subjects and healthy donors (HDs)
The relative percentage of a TRBV family was used to determine relative TRBV use in the CD4 1 T-cell and CD8 1 T-cell subsets. In CD4
1 T cells, we observed seven TRBV gene families with increased expression (BV3, BV11, BV12, BV13.2, BV15, BV20 and BV24) and seven with reduced expression (BV1, BV2, BV4, BV5.1, BV8, BV17 and BV23) (Figure 3a) . Moreover, in CD8 1 T cells, nine TRBV families had increased expression (BV5.1, BV11, BV12, BV13.1, BV13.2, BV15, BV18, BV20 and BV24), and nine TRBV families (BV1, BV2, BV3, BV9, BV14, BV17, BV21, BV22 and BV23) showed a reduction in relative expression ( Figure 3b ).
Monoclonal TRBV profile in CD4 1 and CD8 1 T-cell subsets and PBMCs We identified the monoclonal expansion of TRBV families among CD4
1 T cells, CD8 1 T cells and PBMC populations based on our judgment criteria. Although a single-peak GMSP for a TRBV family may have been detected in any one of the TRBV families derived from the three cell populations (CD4 1 and CD8 1 T-cell subsets and PBMCs), a monoclonal (single peak) TRBV pattern was often detected in the following TRBV families: BV5.1, BV11, BV13.1, BV15, BV20 and BV24 (Table 3) . Representative GMSP profiles of monoclonal TRBV expressed in the CD4 1 and CD8 1 T-cell subsets and in PBMCs are shown in Figures 4 and 5 , respectively. Although monoclonality was identified in different TRBV families within the CD4 1 and CD8 1 T-cell subsets, we cannot discriminate which monoclonal TRBV families were derived from the CD4 1 or CD8 1 T-cell subsets by their GMSP profile shape alone, which was always expressed as a single peak in the GMSP whether the melting temperature was the same. The average skewed expansion ratio of the TRBV families was higher in CD8 1 T-cell population than in the other two cell populations (P,0.01 by x 2 test). d There was no significant difference between the two groups (P.0.05 by x 2 test). Samples with normal GMSPs are excluded from the average ratio calculation. e Normal patterns of GMSPs indicates that there are no monoclonal or oligoclonal patterns in any TRBV gene family in a subject. f The incidence of the normal GMSP was significantly higher in CD4 1 T-cell populations than that in the other two cell populations (P,0.01 by x 2 test).
Conservative CDR3 sequence of monoclonal TRBV in recovered AHI subjects Representative amino acid sequences of TRBV CDR3 from the CD4 1 and CD8 1 T-cell subsets and PBMCs from recovered AHI subjects are shown in Tables 4 and 5 . We observed that the monoclonality of the same or different TRBV CDR3s among different recovered AHI subjects was relatively well conserved, including BV15 (XXXX-GRTNEQ with BJ2.1) and BV12 (XXX-DSYEQ with BJ2.7) in the CD4 1 T-cell subset. We also found CDR3 conservation in TRBV families from different patients in CD8
1 T cells; for example, X-GEL (BJ2.2) and LDYS-XXX-I (BJ1.3) were found in CDR3s from the TRBV11 and BV5.1 families, respectively. In addition, TGTG-XXXX (BJ1.6) was found in the CD4 1 and CD8 1 Tcell subsets and PBMCs from BV20. Moreover, conserved CDR3 motifs from BV15 (XXXX-GRTNEQ with BJ2.1) and BV5.1 (LDYS-XXX-I with BJ1.3) were also found in the PBMC population from recovered AHI subjects, and the 'TEA' (BJ1.1) motif was observed in both TRBV18 and BV17 families. In addition, the relatively conserved CDR3 of TRBV11 was expressed as X-GEL (BJ2.2) or VYNEQ (BJ2.1), respectively, in the PBMC population.
DISCUSSION
HBV infection is an important public health problem with a serious impact on human health. The different clinical stages of chronic HBV infection are determined by the status of the immune response in a host. The T-cell response to HBV is strong in a host with a self-limited acute HBV infection. 6 In addition, the status and function of T cells is reflected in their TRBV profile, and a TCR has three complementary determining regions (CDR1, CDR2 and CDR3). CDR3 primarily recognizes antigen-derived peptides bound to a MHC molecule, an interaction that has been observed through crystal structure analysis. 19, 20 Therefore, the analysis of a CDR3 profile can reveal changes in the T-cell population stimulated by a specific antigen, 21, 22 the amount of a particular T-cell clone and the functional status of T cells. 23, 24 T lymphocytes are primarily divided into the CD4 1 and CD8 1 subsets. In peripheral blood from HDs, the TCRs of more than 95% of T cells are composed of alpha and beta chain heterodimers. 25 The biased clonal expansion of T cells has been identified in the peripheral circulation after a host has been infected with a virus. 5, 7 In this study, we analyzed the extent of oligoclonally or monoclonally skewed, expanded TRBV families in the CD4 1 and CD8 1 T-cell subsets and in PBMCs from recovered AHI subjects and found that the number of skewed TRBV in the CD8 1 fraction was significantly higher than in the CD4 1 T-cell subset and in PBMCs. These observations are consistent with previous reports that indicate that cellular immunity plays a vital role in controlling HBV infection of a host and that clonal proliferation of T cells for HBV specific antigens are mainly found in CD8 1 T cells rather than Figure 1 The number of subjects with a monoclonally expanded TRBV family. The number of subjects with a monoclonal TRBV family is summarized using peripheral CD4 1 or CD8 1 T cells from 30 subjects who have recovered from AHI. AHI, acute hepatitis B virus infection; TRBV, T-cell receptor beta-chain variable. 
in CD4
1 T cells. 26, 27 Moreover, monoclonal TCR transcripts could be detected exclusively in CD8 1 but not in CD4 1 T cells from subjects who had been immunized with a recombinant hepatitis B surface vaccine. 28 The analysis of TRBV usage in an individual can help in the evaluation of the immune response in a variety of conditions over the course of the disease. 29 Many studies have determined that the usage frequency of antigen-specific TRBV families in subjects with either virus infection or cancer can be different. 30, 31 In the current study, the increased expression of several TRBV families was detected in CD4 1 and CD8 1 T-cell populations, which is consistent with observations that the T-cell immune response to HBV antigens involves multiple TRBV families. 32 In addition, these results are consistent with the statement that T-cell immune responses are polyclonal and polyspecific in recovered AHI subjects and involve a number of special TRBV families. Similar results were also found in subjects vaccinated with recombinant HBsAg. 33 These observations may be due to several factors, including the complexity and fluidity of HBV epitopes 34 and the existence of subjects with different HLA phenotypes. In addition, these phenomena may be associated with the structural and spatial configuration of the TCR CDR3, such that different CDR3 sequences may permit the recognition of the same epitope if their molecular spacings are structurally similar. 35 Currently, anti-HBV treatment with nucleoside analogs is used to reduce liver inflammation and to prevent the development of cirrhosis and liver cancer. The curative effect of these None, no skewed TRBV family was detected.
TRBV profile in recovered acute HBV infection subjects JZ Yang et al treatments is closely associated with the restoration of T-cell functionality in the host, particularly the activity of HBV-specific cytotoxic T lymphocyte. 36 In addition, antiviral treatment is often accompanied by side effects and drug resistance. Therefore, there is a pressing need to develop new immunotherapeutic interventions for chronic HBV infection that limit the high costs and risks of toxicity and viral resistance. 37 Methods that modify T cells with antigen-specific TCR genes to treat specific cancers and infectious diseases have attracted significant interest in recent years. In 2006, data from a clinical trial demonstrated that T cells modified with an antigen-specific TCR gene could be used to treat melanoma. 38 It has also been shown that T cells modified with a virus-specific TCR gene are cytotoxic to HBV-infected hepatocytes and a liver cell line expressing an HBV-related antigen. 39 Vizcardo et al.
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transformed antigen-specific T cells into multifunctional T cells and then caused the cells to redifferentiate into T cells with the original antigen-specificity, thereby expanding the potential range of applications for specific T cells. 40 Nishimura et al. 41 reported that CD8 1 T cells isolated from human immunodeficiency virus-1-infected patients could be reprogrammed to generate pluripotent cells 41 that could be differentiated into original antigen-specific T cells with high proliferative activity and telomere length. These reports also showed that T cells modified with an antigen-specific TCR gene have excellent prospects for application in clinical practice. 42 In this report, we found that the TRBV families TRBV5.1, BV11, BV13.1, BV15, BV20 and BV24 were more frequently expanded monoclonally than other TRBV family members in recovered AHI subjects, regardless of the presence of CDR3 in the CD4 1 or CD8 1 T-cell subsets, further demonstrating that the T-cell immune response was polyclonal and polyspecific in the recovered AHI subjects studied. 43 This phenomenon was also discovered in the peripheral blood of patients with chronic 
Figure 3 Relative frequencies of each TRBV gene family in the CD4 1 and CD8 1 T cell subsets from recovered AHI subjects and HDs. PBMCs from recovered AHI subjects (open bars) and HDs (filled bars) were sorted into CD4 1 (A) and CD8 1 (B) T-cell subsets. Data represent the relative percentages (%) of each TRBV gene family . The data are presented as the mean and standard deviation (s.d.) of the relative expression of each TRBV from 30 recovered AHI subjects and 20 HDs. *P,0.05; **P,0.01. AHI, acute hepatitis B virus infection; HD, healthy donor; PBMC, peripheral blood mononuclear cell; recovered AHI subjects, subjects who have recovered from AHI; TRBV, T-cell receptor beta-chain variable.
hepatitis B, although the prevalent usage of TCR was lower than that of the recovered AHI subjects 44, 45 and may be associated with the different immune response ability between them.
In addition, we analyzed the HLA types of subjects with prominent TRBV families to determine whether the relatively conserved CDR3 sequence was associated with a common HLA phenotype (Supplementary Table 2 ). These results indicated that the identity of the conserved CDR3 sequences in recovered AHI subjects were independent of the similarity in their HLA alleles. Moreover, the recognition of antigen by specialized T cells is controlled by MHC-restricted T cells. Our results of relatively conserved CDR3 motifs in the independent HLA phenotypes of recovered AHI subjects may be associated with the CDR reaction to the complex of peptide-MHC with plasticity and cross reactivity. 46, 47 In future studies, we plan to demonstrate the association of other HLA genotypes in combination with skewed TRBV families with HBV subgenotypes in more cases, in which we could discover the relationship between the HLA phenotypes and the relatively conserved TRBV families.
Additionally, many HBV T-cell epitopes were identified. In this study, we found several prevalent TRBV families that may be specific for HBV-related antigens; however, it is hard to determine to which peptides from HBV these T cells (TRBV) react because more than one quintillion TCR combinations can be generated by somatic recombination, in theory. 48 Nevertheless, the determined prevalence of TRBV families can provide a key clue for establishing a TRBV profile as being specific for a specific HBV peptide.
In the production of antibodies in a host infected with an infectious disease, cells from the CD4 1 T-cell subset (Th) play a vital role in helping B cells produce antigen-specific antibodies. 49 We found that several skewed TRBV families (BV11, BV12, BV15 and BV20) had relatively higher usage and expression than other TRBV families in the CD4 1 T-cell subset, indicating that these TRBV families were associated with the HBsAb produced in the recovered AHI subjects. Furthermore, TRBV15 from the CD4 1 subset had the highest rate of use and relatively higher expression in recovered AHI subjects, suggesting that the TRBV family was most likely associated with the emergence and maintenance of HBsAb. In addition, the six TRBV families BV5.1, BV11, BV13.1, BV15, BV20 and BV24 have a higher rate of use and relative expression of the 24 TRBV families in recovered AHI subjects. This was particularly true for the TRBV families derived from the CD8 1 T-cell subset, which is consistent with previous reports. 26 These results suggested that multiple TRBV families, primarily derived from CD8 1 T cells, were involved in the response against HBV antigens in recovered AHI subjects; however, these observations should be further confirmed with more cases in future studies.
In summary, the molecular characteristics of TRBV in subjects recovered from AHI are biased and involve multiple TRBV families. The TRBV11, BV12, BV15 and BV20 families in the CD4
1 T-cell subset may have contributed more to the Figure 4 A representative GMSP with a single-peak (monoclonal expansion) for TRBV families in the CD4 1 and CD8 1 T-cell subsets in recovered AHI subjects. The TRBV families shown in the top graphs correspond to S10 CD4 1 (BV20), S9 CD4 1 (BV18), S5 CD4 1 (BV15), S8 CD4 1 (BV15), S11 CD4 1 (BV12) and S20 CD4 1 (BV5.1), and the TRBVs shown in the bottom graphs correspond to S2 CD8 1 (BV24), S4 CD8 1 (BV20), S5 CD8 1 (BV11), S8 CD8 1 (BV11), S12 CD8 1 (BV5.1) and S19 CD8 1 (BV5.1). The corresponding amino-acid sequences are shown in Table 4 . The melting temperature is on the x-axis of each plot. The negative first derivative of the reduction in fluorescence as a function of temperature (2dF/dT) is shown on the y-axis. AHI, acute hepatitis B virus infection; GMSP, gene melting spectral pattern; TRBV, T-cell receptor beta-chain variable. Figure 5 A representative GMSP with a single peak (monoclonal expansion) of the TRBV families in PBMCs from recovered AHI subjects. The TRBV families shown in the top graphs correspond to S1 (BV20), S15 (BV20), S6 (BV18), S3 (BV17), S1 (BV15) and S9 (BV13.2), and the TRBVs shown in the bottom graphs correspond to S12 (BV13.1), S5 (BV12), S2 (BV11), S16 (BV9), S32 (BV5.1) and S15 (BV3). The corresponding amino-acid sequences are shown in Table 5 . The melting temperature is on the x-axis of each plot. The negative first derivative of the reduction in fluorescence as a function of temperature (2dF/dT) is shown on the y-axis. AHI, acute hepatitis B virus infection; GMSP, gene melting spectral pattern; PBMC, peripheral blood mononuclear cell; TRBV, T-cell receptor beta-chain variable. Abbreviations: AHI, acute hepatitis B virus infection; BJ, T-cell receptor beta joint region; CDR3, complementary determining regions; PBMC, peripheral blood mononuclear cell; TRBV, T-cell receptor beta-chain variable; Vbeta, T-cell receptor beta-chain variable region. When the GMSP of a TRBV gene family displayed a single peak (Figure 4) , the PCR product of the corresponding TRBV gene family was re-amplified, and the PCR product was sequenced after cloning. Only the amino acid sequences of the CDR3 max ratio are shown. The identical amino acids in the CDR3 sequences are underlined. a The T-cell subset used for analysis is in brackets.
emergence and maintenance of HBsAb in recovered AHI subjects, and TRBV11, BV15 and BV20, all of which were preferentially detected in the T-cell subsets and in PBMCs and may have been relevant to the pathogenesis and positive outcome of subjects with AHI. Furthermore, the prevalent use of TRBV5.1 and BV20, which have relative conservative amino acid sequences, would help with the diagnosis of chronic HBV infection and the provision of individualized treatment with specific T cells modified with antigen-specific TCR genes. Abbreviations: AHI, acute hepatitis B virus infection; BJ, T-cell receptor beta joint region; CDR3, complementary determining regions; PBMC, peripheral blood mononuclear cell; TRBV, T-cell receptor beta-chain variable; Vbeta, T-cell receptor beta-chain variable region.
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When the GMSP of a TRBV gene family displayed a single peak ( Figure 5 ), the PCR product of the corresponding TRBV gene family was re-amplified, and the PCR product was sequenced after cloning. Only the amino-acid sequences of the CDR3 max ratios are shown. The identical sequences are underlined.
